ArticleThe World Allergy Organization journal2021
Biologics and global burden of asthma: A worldwide portrait and a call for action.
Article in The World Allergy Organization journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in asthmatic children: a systematic review with meta-analysis.European journal of pediatrics · 2026Pooled it
- The future of allergy and immunology care: A perspective on innovation, equity, and global collaboration from the WAO Junior Members Group.The World Allergy Organization journal · 2026Article
- Asthma and Sinonasal Diseases: Shared Clinical Comorbidities, Inflammatory Pathways and Management Strategies.Medical sciences (Basel, Switzerland) · 2026Review
- Prevalence and cost implications of broadening asthma biologic eligibility criteria.The World Allergy Organization journal · 2026Article
- Global Asthma Disparities: Deciphering the Multifaceted Environmental Exposome Between Eastern and Western Populations.Clinical reviews in allergy & immunology · 2026Review
- Article
- Biological treatments for asthma and chronic obstructive pulmonary disease.BMJ medicine · 2026Review
- Precision Medicine for Asthma: Tailored to its Severity and Endotype/Phenotype.Allergy, asthma & immunology research · 2026Review
- Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory experts.Frontiers in allergy · 2026Review
- Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review.The World Allergy Organization journal · 2025Article
- Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study.Advances in therapy · 2025Observational
- The value of treatable traits across the spectrum of adult asthma severity.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Review
- Pharmacogenetics of childhood uncontrolled asthma.Expert review of clinical immunology · 2025Review
- Association of LPCAT1-rs8352 genetic variant with susceptibility and severity of pediatric bronchial asthma: a case-control study.BMC pediatrics · 2025Article
- Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.Frontiers in pharmacology · 2025Review
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- The new biologic drugs: Which children with asthma should get what?Pediatric pulmonology · 2024Review
- Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).Advances in therapy · 2024Observational
- In mouse model of mixed granulocytic asthma with corticosteroid refractoriness, Bronchom mitigates airway hyperresponsiveness, inflammation and airway remodeling.Molecular medicine (Cambridge, Mass.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease. A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall "asthma management system" in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.